ClinicalTrials.gg
CompletedNCT06877624Updated Aug 26, 2025

A Study Evaluating the Pharmacokinetics of Three QRL-101 Formulations in Healthy Participants

A Phase 1 interventional study of QRL-101 in Healthy Volunteers, sponsored by QurAlis Corporation. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-26.

Sponsored by QurAlis Corporation · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This study aims to evaluate the pharmacokinetics of three QRL-101 formulations in a fasted condition or in the presence of a high-fat meal in healthy participants.

Read the detailed description

This is a randomized, open-label, single-dose, crossover study to evaluate the PK of three formulations of QRL-101 beginning in a fasted condition before moving to a fed cross-over design. Approximately 24 healthy participants will be enrolled in a 3-formulation, 4-period, 6-sequence crossover study design to evaluate the PK characteristics of three formulations of QRL-101.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Healthy Volunteers
03

In context

Lead sponsor

QurAlis Corporation is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 to 70 years of age inclusive at the time of signing the .
  2. Clinical chemistry laboratory values within acceptable range for the population, as per investigator judgment.
  3. of 18 to 32 kg/m2 (inclusive).
  4. Willing and able to practice effective .

Exclusion criteria

Exclusion Criteria:

  1. Currently enrolled in any other clinical trial involving a study drug or off-label use of a drug or device, or any other type of medical research judged not to be scientifically or medically compatible with this study.
  2. Any participant in >4 studies a year and/or has participated in a clinical trial within 1 month of the expected dosing date.
  3. History or presence of medical illness including, but not limited to, any cardiovascular, hepatic, respiratory, hematological, endocrine, psychiatric, or neurological disease, convulsions, or any laboratory abnormality that, in the judgment of the investigator, indicate a medical problem that would preclude study participation.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Treatment Sequence 1 (Formulation 1, 2, and 3)

    Participants randomized to Treatment Sequence 1 will receive Formulation 1 in the fasted condition in Treatment Period 1, followed by Formulation 1, 2, and 3 in the presence of a high-fat meal in Treatment Periods 2 through 4, respectively.

    Drug: QRL-101

  • Experimental
    Treatment Sequence 2 (Formulation 2, 3, and 1)

    Participants randomized to Treatment Sequence 2 will receive Formulation 2 in the fasted condition in Treatment Period 1, followed by Formulation 2, 3, and 1 in the presence of a high-fat meal in Treatment Periods 2 through 4, respectively.

    Drug: QRL-101

  • Experimental
    Treatment Sequence 3 (Formulation 3, 1, and 2)

    Participants randomized to Treatment Sequence 3 will receive Formulation 3 in the fasted condition in Treatment Period 1, followed by Formulation 3, 1, and 2 in the presence of a high-fat meal in Treatment Periods 2 through 4, respectively.

    Drug: QRL-101

  • Experimental
    Treatment Sequence 4 (Formulation 2, 1, and 3)

    Participants randomized to Treatment Sequence 4 will receive Formulation 1 in the fasted condition in Treatment Period 1, followed by Formulation 1, 3, and 2 in the presence of a high-fat meal in Treatment Periods 2 through 4, respectively.

    Drug: QRL-101

  • Experimental
    Treatment Sequence 5 (Formulation 2, 1, and 3)

    Participants randomized to Treatment Sequence 5 will receive Formulation 2 in the fasted condition in Treatment Period 1, followed by Formulation 2, 1, and 3 in the presence of a high-fat meal in Treatment Periods 2 through 4, respectively.

    Drug: QRL-101

  • Experimental
    Treatment Sequence 6 (Formulation 3, 2, and 1)

    Participants randomized to Treatment Sequence 6 will receive Formulation 3 in the fasted condition in Treatment Period 1, followed by Formulation 3, 2, and 1 in the presence of a high-fat meal in Treatment Periods 2 through 4, respectively.

    Drug: QRL-101

Interventions

  • This cross-over design study will evaluate three formulations (Formulations 1, 2, and 3) of QRL-101, beginning in a fasted condition before moving to a fed cross-over design.

06

What researchers measure

Primary outcomes

  1. Plasma PK profile (AUCinf)

    The area under the curve to infinity

    Time frame: Baseline through Follow up (Day 9)

  2. Plasma PK profile (AUClast)

    The area under the curve to the last measurable time point

    Time frame: Baseline through Follow up (Day 9)

  3. Plasma PK profile (Cmax)

    Maximum concentration observed

    Time frame: Baseline through Follow up (Day 9)

  4. Plasma PK profile (Ctrough)

    Trough level concentration for defined dose regimen

    Time frame: Baseline through Follow up (Day 9)

  5. Plasma PK profile (Tmax)

    The time to peak drug concentration

    Time frame: Baseline through Follow up (Day 9)

Secondary outcomes

  1. Safety and tolerability

    Adverse events (AEs) and serious adverse events (SAEs)

    Time frame: Baseline through Follow up (Day 9)

07

Study locations

1 site
  • ICON plc. Van Swietenlaan 6
    Groningen, 9728 NZ, Netherlands
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2025 to primary completion in May 2025, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2025
First posted
Mar 14, 2025
StartActual
Jan 10, 2025
Primary completionActual
May 15, 2025
CompletionActual
May 15, 2025
Last update
Aug 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06877624
Lead sponsor
QurAlis Corporation
Responsible party
Sponsor
First posted
Mar 14, 2025
Start date
Jan 10, 2025
Primary completion
May 15, 2025
Completion
May 15, 2025
Last update
Aug 26, 2025

Study contacts

Salah Hadi, MD
principal investigator · ICON plc

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: QRL-101

Start the discussion